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Abstract
Objective—The objective of the present study was to determine the diagnostic performance of 
the symptom-based tuberculosis (TB) screening questionnaire recommended by WHO for people 
living with HIV (PLWH) in resource-limited settings, among adults off and on antiretroviral 
therapy (ART).
Design—Cross-sectional study at two HIV clinics in South Africa.
Methods—A total of 825 PLWH completed the screening questionnaire and underwent 
investigations [chest radiography (CXR) and microbiologic testing of sputa]. A positive screen 
was defined as presence of cough, fever, night sweats, or weight loss. Pulmonary tuberculosis 
(PTB) was defined as sputum smear positive for acid-fast bacilli or growth of Mycobacterium 
tuberculosis.
Results—Of 737 participants with at least one diagnostic sputum specimen, PTB was diagnosed 
in 31 of 522 (5.9%) on ART, and 34 of 215 (15.8%) not on ART. The questionnaire missed 15 of 
31 (48.4%) PTB cases on ART, and three of 34 (8.8%) not on ART. Among participants on ART, 
post-test probability of PTB diagnosis (95% confidence interval) was 6.8% (4.0–10.9%) if 
screening positive, and 5.2% (2.9–8.4%) if screening negative, whereas among participants not on 
ART, post-test probabilities were 20.3% (14.2–27.5%) and 4.8% (1.0–13.5%), respectively. 
Among participants diagnosed with PTB, those on ART were significantly less likely to screen 
positive (adjusted odds ratio 0.04, 95% confidence interval: 0.01–0.39). In both groups (ART and 
no ART), screening was more sensitive when CXR was incorporated.
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Conclusion—For case detection and exclusion of PTB, the WHO-recommended questionnaire 
performed adequately among PLWH not on ART, and poorly among those on ART. Further 
research is needed to identify feasible and effective TB screening strategies for PLWH in resource-
limited settings.
Keywords
antiretroviral therapy; HIV; resource-limited settings; screening; tuberculosis
Introduction
People living with HIV (PLWH) are at increased risk of developing and dying from 
tuberculosis (TB). In areas where HIV-associated TB is prevalent, routine screening for TB 
among PLWH is recommended in order to detect cases earlier, and to exclude TB prior to 
initiating isoniazid preventive therapy (IPT). The latter two objectives are anticipated to 
result in a decrease of TB-related morbidity and mortality. The WHO recommends using a 
symptom-based questionnaire for TB screening among PLWH in resource-constrained 
settings [1]. The questionnaire categorizes patients into two groups: asymptomatic 
individuals in whom IPT can be initiated, and symptomatic individuals (i.e., TB suspects) 
requiring further evaluation to exclude TB. The recommended questionnaire was selected 
based on a meta-analysis of screening studies in adult PLWH [2].
In high TB and HIV burden settings, HIV-associated TB remains a significant cause of 
morbidity and mortality even among persons on antiretroviral therapy (ART) [3,4]. 
However, few data from adults on ART were included in the meta-analysis which motivated 
the selection of the recommended screening questionnaire [2]. Since the meta-analysis was 
published, two reports from South Africa have described the performance of symptom-based 
screening among adults on ART and arrived at disparate conclusions [5,6]. In the larger of 
the two studies (N = 1429), diagnostic performance was inferior among participants on ART 
compared with those not taking ART [5], whereas in the smaller study (N = 422), symptom-
based screening was highly sensitive regardless of ART status [6]. Importantly, neither study 
evaluated screening strategies that incorporated chest radiography (CXR) in the screening 
process.
In South Africa, where both HIV and TB are highly prevalent, the number of PLWH 
receiving ART has increased substantially over the past decade (75% in the last 2 years) [7]. 
Increases in ART uptake have also been achieved elsewhere [7]. As more PLWH are 
receiving ART, it is critically important to define the TB screening questionnaire's 
performance among PLWH on ART.
Methods
Our primary objective was to compare the performance of the WHO-recommended 
symptom-based screening questionnaire for the diagnosis of pulmonary TB (PTB) in adult 
PLWH on ART and those not taking ART at two HIV clinics in South Africa. As a 
secondary objective, we sought to evaluate diagnostic performance of a screening strategy 
utilizing CXR and the questionnaire.
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Study population
The study was conducted at two HIV care and treatment clinics in Eastern Cape Province, 
supported by ICAP-Columbia University. Xhosa-speaking or English-speaking PLWH at 
least 18 years old and able to provide informed consent were eligible for enrollment, 
irrespective of ART status. Patients on TB treatment or awaiting results of TB investigations 
were ineligible.
Study procedures
Between March 2011 and January 2012, a TB screening questionnaire was administered to 
all PLWH attending routine clinic visits. The questionnaire was available in English as part 
of the provincial Adult Clinical Record and administered by clinic providers, as per routine 
practice, in the patient's preferred language. Patients interested in study participation were 
assessed for eligibility and enrolled by trained research assistants. After providing written 
informed consent in English or Xhosa, participants submitted three sputum specimens (spot/
morning/spot) for microbiologic testing (three smears and one mycobacterial culture) and 
underwent CXR regardless of questionnaire responses. Spot sputa were induced using 
nebulized hypertonic saline with adherence to infection control protocols to minimize 
transmission risk.
Induced sputa were examined onsite using direct smear microscopy (Kinyoun staining for 
light microscopy at Hospital A; fluorescence microscopy at Hospital B). Within 48 h after 
collection, early morning sputa were refrigerated and transported to a referral laboratory 
where, after decontamination, fluorescence microscopy and liquid mycobacterial cultures 
were performed (BACTEC MGIT 960). Laboratories had established quality assurance 
programs.
At each study site, radiographs were interpreted by a designated physician trained to read 
CXR in a standardized fashion and blinded to screening results.
Age, sex, height, weight, HIV care enrollment date, ART initiation date, ART regimen, 
history of previous TB, use of IPT, CD4+ cell count, screening questionnaire responses, and 
results of TB investigations were abstracted from medical charts using a standardized form.
The protocol was approved by Institutional Review Boards of the University of Cape Town 
and Columbia University Medical Center, the research review committees of the Eastern 
Cape Department of Health and of the East London Hospital Complex.
Statistical analysis
Because symptoms could change with time, we excluded smear and culture results from 
sputa submitted more than 14 days after the questionnaire was administered. Our analyses 
excluded participants not submitting sputa and those submitting all specimens more than 14 
days after enrollment.
As per South African guidelines [8], PTB was defined as presence of at least one sputum 
smear positive for acid-fast bacilli or for growth of Mycobacterium tuberculosis in culture.
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A positive screen was defined as presence of at least one symptom (fever, cough, night 
sweats, or weight loss) at study enrollment (determined using the questionnaire) [1]. For our 
secondary objective, a positive screen was defined as presence of at least one symptom or 
any abnormal CXR finding.
We described participant characteristics stratified by ART status. Statistical significance was 
assessed with Mann–Whitney U-tests, continuity-adjusted x2, or Fisher's exact tests, with 
significance threshold of P < 0.05.
For both the screening questionnaire and the screening strategy including the questionnaire 
and CXR, we calculated point estimates and 95% confidence intervals (CIs) of the following 
operating characteristics: sensitivity, specificity, positive predictive value, negative predictive 
value (NPV), positive likelihood ratio, and negative likelihood ratio.
To assess for effect modification by ART use on the questionnaire's sensitivity and 
specificity, we performed regression analyses stratified by presence or absence of PTB in 
which the dependent variable was the result of the screening questionnaire [9]. In the 
analysis restricted to participants with PTB (to determine whether ART modified 
sensitivity), possible outcomes for the questionnaire were ‘true-positive’ or ‘false-negative,’ 
and the odds ratio (OR) for ART status compared the odds of a true-positive screen among 
participants on ART to odds of a true-positive screen among those not taking ART. In the 
model restricted to participants without PTB (for effect modification on specificity), the 
possible outcomes were ‘true-negative’ or ‘false-positive.’
Crude and adjusted ORs were calculated using logistic regression. Covariates included study 
site, sex, age, history of previous TB, duration of enrollment in HIV care, BMI, CD4+ cell 
count, and abnormal CXR findings. Model fit was assessed using the Hosmer–Lemeshow 
statistic.
In post-hoc sensitivity analyses, we restricted our definition of PTB to growth of M. 
tuberculosis in culture.
Results
We enrolled 825 participants. While enrollment was ongoing and prior to analysis, data from 
the first 73 enrolled at one of the sites were removed because of concerns about data 
integrity. Fifteen participants were excluded because sputa were submitted more than 14 
days after enrollment. Supplement Figure S1, http://links.lww.com/QAD/A511 describes 
recruitment, enrollment, and exclusion.
Participant characteristics
Table 1 describes characteristics of the 737 participants, of whom 522 (70.8%) were on ART 
at study enrollment. Participants on ART were more likely to have a history of previous TB 
and had higher median CD4+ cell count, BMI, and duration of enrollment in care compared 
with those not taking ART (P < 0.001 for all). Among participants on ART, 8.2% (N = 43) 
had been on ART for less than 3 months. All questionnaire symptoms were less common 
among PLWH on ART (P < 0.001).
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Three smears and one culture were performed for 78.4% (N = 578) of participants, and 
culture results were available for 82.9% (N = 611), with no differences noted by ART status. 
CXR was performed in 95.7% (N = 705) of participants.
Pulmonary tuberculosis
Sixty-five participants (8.8%) were diagnosed with PTB, 31 of 522 (5.9%) on ART and 34 
of 215 (15.8%) not on ART (Table 2). Compared with those not diagnosed with PTB, 
participants with PTB were significantly less likely to be on ART (P < 0.001) and to have a 
history of previous TB (P < 0.001), and had lower median CD4+ cell count (P = 0.01), BMI 
(P < 0.001), and duration of enrollment in care (P = 0.02).
Most PTB was smear-negative and culture-positive [ART: 48.4% (N = 15); no ART: 64.7% 
(N = 22)], followed in frequency by smear-positive and culture-positive [ART: 32.3% (N = 
10); no ART: 32.4% (N = 11)]. Five participants on ART (16.1%) and one not on ART 
(2.9%) were smear-positive and culture-negative. Culture results were missing for one 
smear-positive participant on ART.
Performance of the screening questionnaire
Sensitivity was lower, and specificity higher, among participants on ART as compared with 
those not on ART (Table 3). NPV was similar in both groups. In the ART group, the 
questionnaire was not useful for distinguishing between participants with and without PTB 
diagnosis: post-test probability of PTB was 6.8% (95% CI: 4.0–10.9%) after a positive 
screen and 5.2% (95% CI: 2.9–8.4%) after a negative screen. In the no ART group, post-test 
probability of PTB was 20.3% (95% CI: 14.2–27.5%) and 4.8% (95% CI: 1.0–13.5%) 
among those screening positive and negative, respectively.
In both ART and no ART groups, the questionnaire identified most PTB cases among the 
minority – that is, 21 of 65 – that were both smear-positive and culture-positive [ART: 
90.0% (N = 9); no ART: 100% (N = 11)]. In the no ART group, the questionnaire identified 
most smear-negative culture-positive, or smear-positive culture-negative/missing PTB 
[86.9% (N = 20)]; however, few of these cases were identified among those on ART [33.3% 
(N = 7)].
Table 4 summarizes the operating characteristics of the screening strategy in which a 
positive screen was defined as the presence of any symptom or an abnormal CXR. Among 
participants on ART, compared with the use of the questionnaire alone, this strategy's 
sensitivity was higher (76.7 vs. 51.6%) and specificity lower (27.4 vs. 55.8%), whereas 
among those not on ART, the predominant effect was a lower specificity (15.5 vs. 32.6%). In 
both ART and no ART groups, post-test probabilities of PTB were similar to those using the 
questionnaire alone. As shown in Supplement Table S1 (see Supplemental Digital Content, 
http://links.lww.com/QAD/A511), sensitivities were unchanged, and specificities slightly 
higher if CXR criterion for a positive screen was an abnormality suggestive of TB instead of 
any abnormality.
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Participant characteristics associated with sensitivity and specificity of the screening 
questionnaire
The questionnaire's sensitivity was significantly lower among participants on ART in both 
bivariable and multivariable analyses (Table 5). Conversely, the questionnaire's specificity 
was significantly higher among persons on ART. In multivariable analyses, both abnormal 
CXR and BMI were associated with specificity; the former was also associated with 
sensitivity.
Performance of questionnaire for the diagnosis of culture-confirmed pulmonary 
tuberculosis
When PTB was defined as growth of M. tuberculosis in culture, six smear-positive culture-
negative participants were categorized as not having PTB (five on ART and one not on 
ART). This analysis excluded one smear-positive participant because of missing culture 
results (on ART) and 124 smear-negative participants for whom sputa for culture were not 
submitted, submitted more than 14 days after enrollment, or nondiagnostic. In the ART 
group (N = 424), questionnaire sensitivity was 60.0% (95% CI: 38.7–78.9%); and post-test 
probability of PTB was 7.7% (95% CI: 4.4–12.4%) among those screening positive, and 
4.3% (95% CI: 2.1–7.8%) among those screening negative. In the no ART group (N = 188), 
sensitivity was 93.9% (95% CI: 79.8–99.3%), and post-test probabilities 22.5% (95% CI: 
15.8–30.3%) and 4.0% (95% CI: 0.5–13.7%) for a positive and negative screen, respectively. 
ART status remained strongly associated with sensitivity and specificity in multivariable 
analyses. Supplemental Tables S2 and S3, http://links.lww.com/QAD/A511 report the full 
results of this analysis.
Discussion
In this study of TB screening among adult PLWH in South Africa, the diagnostic 
performance of the WHO-recommended symptom-based questionnaire was limited and 
varied by ART status. Among participants on ART, the questionnaire had low sensitivity and 
was not useful for differentiating those with and without PTB. Among participants not 
taking ART, the questionnaire was highly sensitive and diagnostically useful. Sensitivity was 
improved, particularly for those on ART, with incorporation of CXR in the screening 
strategy. An association between ART status and diagnostic performance was also observed 
after controlling for potential confounders, and in post-hoc analyses in which only culture-
confirmed cases were categorized as PTB.
Our findings have major implications for the utility of the WHO-recommended TB 
screening questionnaire. In the meta-analysis used to derive the questionnaire, in which 
nearly all data came from PLWH not on ART, the authors reported important between-study 
heterogeneity in diagnostic performance [2]. The questionnaire's diagnostic performance 
among PLWH not on ART in our study is consistent with that reported in the meta-analysis 
[2], but conflicts with recent reports of poor sensitivity in the same population [10] and in 
antenatal clinics [11]. Between-study heterogeneity is now also evident for the 
questionnaire's performance among PLWH on ART. For culture-confirmed TB, the 
questionnaire's sensitivity was lowest in the study by Rangaka et al. (23.8%), followed by 
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our study (60%), and highest in the study by Kufa et al. (100%). The converse was true for 
specificity, which was highest in the study by Rangaka et al. (94.4%), followed by our study 
(55.1%), and the study by Kufa et al. (18.1%). This diagnostic heterogeneity was seen 
despite similar settings and reported participant characteristics, raising the question of what 
factors (such as viral load, opportunistic infections, or language) could explain these 
differences, and underscoring the need for further research.
There are a number of possible explanations for the observed association between ART use 
and the questionnaire's diagnostic performance. First, it is possible that a greater proportion 
of TB cases on ART were in an early, and hence asymptomatic, phase of TB, compared with 
cases not on ART. Second, ART use may have affected the diagnostic performance by 
promoting immune reconstitution, thereby preventing other opportunistic illnesses 
(including extrapulmonary TB) that could cause a positive screen. The lower sensitivity and 
greater specificity of the questionnaire among those on ART support this hypothesis. Finally, 
sensitivity may have been lower among participants on ART if they were more likely to have 
been previously screened for TB than those not on ART [2,12,13]. However, such 
differential TB screening is unlikely, as all PLWH should have been screened for TB at 
enrollment into HIV care and at each routine clinic visit as per national guidelines.
It is possible the questionnaire's sensitivity is higher during the initial months of ART when 
immune reconstitution ‘unmasks’ TB that was prevalent, but asymptomatic prior to ART 
[14]. There were too few participants on ART for less than 3 months in our study (N = 43, 
8.2%) to permit meaningful exploration of this hypothesis. Our findings are thus most 
generalizable to PLWH who have been on ART for more than 3 months. Further studies are 
needed to establish the questionnaire's diagnostic performance during the early phase of 
ART use.
To our knowledge, ours is the first study to report performance of CXR in TB screening 
among PLWH on ART. Because prevalence of abnormal findings on CXR was high 
irrespective of PTB diagnosis, incorporation of CXR into the screening strategy increased 
sensitivity and decreased specificity of TB screening for participants on ART. Similar results 
have been reported among ART-naive populations [10,12,15,16], with sensitivity reaching 
over 90% in three studies [10,15,16]. Further research is warranted to verify our findings, as 
we were unable to assess inter-reader variability.
In high HIV and TB burden settings, PLWH remain at increased risk of TB even after 
several years of ART [3]. In such settings, routine TB screening among PLWH is expected 
to lower morbidity and mortality through earlier case detection, and by expediting the 
exclusion of TB prior to IPT [1]. The questionnaire's poor sensitivity among participants on 
ART is concerning – it suggests the questionnaire is not useful for active case finding in this 
group. However, the questionnaire mostly failed to identify TB cases that were smear-
negative culture-positive, and smear-positive culture-negative, the majority of cases. Some 
have questioned the clinical relevance of identifying these cases prior to symptom onset, 
arguing that a false-negative screen will result in poor treatment outcomes only if TB 
becomes substantially more extensive before it is diagnosed [17], a situation that could arise 
with infrequent follow-up or screening. However, even if initiation of PTB treatment in the 
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early stages of disease as opposed to once disease is symptomatic does not improve 
treatment outcomes, it may be important for preventing transmission in household, 
community, and healthcare settings [18–20].
Fear of generating isoniazid-resistant TB is often cited as a reason for not prescribing IPT 
[21,22], although proponents of IPT note that a meta-analysis and recent cluster randomized 
trials have shown the risk of developing isoniazid-resistant TB following IPT is minimal 
[23–25]. However, none of the studies in the meta-analysis, nor the cluster randomized trials, 
relied solely on symptom-based screening to exclude TB prior to IPT initiation. In the meta-
analysis, which pooled results from six studies of IPT in PLWH, five studies used both 
symptom-based screening and CXR to exclude TB prior to IPT, and two studies also used 
sputum smear and culture [23]. In the two cluster randomized trials, participants were 
screened with both symptoms and CXR prior to IPT [24,25]. With the use of a less sensitive 
tool such as the screening questionnaire, the risk of developing isoniazid-resistant TB may 
be higher in populations in whom TB is common (as a greater proportion of those starting 
IPT will already have TB).
In our study, if only the symptom-based questionnaire was used to exclude TB prior to IPT, 
then among persons receiving isoniazid, 3.0% on ART and 1.6% not on ART would be cases 
of asymptomatic TB exposed to isoniazid monotherapy, roughly the same proportions 
expected to benefit from nontuberculin skin test (TST)-targeted IPT [26,27]. Screening with 
tests more sensitive than the questionnaire alone, and targeting IPT to TST-positive patients 
[25,28], will help ensure the probability of benefit from IPT outweighs the risk of 
inadvertent isoniazid monotherapy among PLWH, both on and off ART.
Our study has a number of strengths. First, the study included a large number of participants, 
both on and off ART. Second, use of sputum induction is likely to have increased the 
proportion of participants with TB who were identified by smear status. Third, our study was 
conducted under programmatic conditions in a resource-constrained area and our results are 
generalizable to settings in which the questionnaire is used.
Our study also has limitations. First, if smear-positive culture-negative specimens were due 
to laboratory error rather than PTB, then classification of participants with these results as 
having PTB spuriously lowered the sensitivity among those taking ART. Second, 17.1% of 
participants did not have culture results, which could have resulted in missed cases of PTB. 
However, results in post-hoc analysis addressing both limitations were similar to the primary 
analysis. Third, the routinely collected data used for some participant characteristics were 
incomplete or may not have reflected values at the time of study enrollment. Fourth, we did 
not assess inter-reader reliability for CXR interpretation. Fifth, each hospital used a different 
method to read smears; however, the proportion of positive smears was not significantly 
different between the hospitals (data not shown) and all multivariable models adjusted for 
site. A final limitation is that we were unable to determine whether using the questionnaire 
as the sole method of TB screening increases the risk of poor outcomes.
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Conclusion
We found the WHO-recommended TB screening questionnaire performs adequately among 
PLWH not taking ART, and poorly among those on ART. This has important implications as 
the population of PLWH on ART is growing rapidly and their TB risk remains elevated in 
high TB burden areas. Research is needed to better understand the determinants of 
diagnostic heterogeneity of symptom-based TB screening in PLWH, both within and 
between populations on and off ART. There is also a need for prospective implementation 
studies, which follow PLWH screened with the WHO-recommended questionnaire to 
determine subsequent TB incidence, drug resistance, and treatment outcomes. Finally, there 
remains a need to identify inexpensive TB screening strategies for PLWH in resource-
limited settings with higher sensitivity and less diagnostic heterogeneity. The increasing 
availability of the Xpert MTB/RIF assay provides an opportunity to operationally explore its 
role in routine TB screening in resource-limited settings.
Our study also has implications for screening policies in settings in which TB is common 
among PLWH. To lower risks of exposing PLWH on ART with unrecognized TB to 
isoniazid monotherapy, it may be prudent to combine the screening questionnaire with CXR 
or perform sputum cultures regardless of symptom status. It may be safer to use one of these 
more sensitive screening strategies even among PLWH who are not on ART, particularly if 
IPT is not targeted to TST-positive persons. The resources required to implement such 
screening are unavailable in many places where TB is prevalent among PLWH. The limited 
effectiveness of symptom-based screening in our study, and results of an analysis 
demonstrating the cost–effectiveness of TB screening with GeneXpert or sputum culture 
regardless of symptoms in South Africa [29], support scale-up of TB diagnostic capacity in 
areas burdened by TB-HIV coinfection.
In settings where the questionnaire remains the sole method of TB screening prior to IPT 
initiation, implementing the WHO recommendation that PLWH be screened for TB during 
every follow-up visit regardless of IPT status [1], and performing drug susceptibility testing 
in all PLWH who develop TB on IPT, may help avoid important delays in TB treatment 
initiation and detection of drug-resistant TB among those with an initial negative screen.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Participant characteristics and symptoms stratified by antiretroviral therapy status (N = 737)a,b.
Characteristics ART, N (%) No ART, N (%)
522 (71) 215 (29)
Study site
    Hospital A 278 (53) 112 (52)
    Hospital B 244 (47) 103 (48)
Sex
    Male 123 (24) 52 (24)
    Female 399 (76) 163 (76)
Median age, years (IQR) 36.9 (31.4–45.2) 35.6 (29.7–44.1)
Previous TBc 232 (44) 52 (24)
Median CD4+ cell count (cells/μl) (IQR)c 365 (229–510) 200 (85–303)
Median BMI (kg/m2) (IQR)c 24.4 (21.2–28.3) 23.1 (20.4–27.6)
Median duration of enrollment in HIV care (days) (IQR)c 1150 (592–2031) 76 (7–653)
Median duration of ART (days) (IQR) 786 (433–1455) –
Symptomsc
    Fever, N (%) 36 (7) 32 (15)
    Cough, N (%) 156 (30) 99 (46)
    Night sweats, N (%) 100 (19) 65 (30)
    Weight loss, N (%) 89 (17) 108 (50)
    Positive screen (any symptom), N (%)c 233 (45) 153 (71)
aART, antiretroviral therapy; IQR, interquartile range; TB, tuberculosis.
b
Data missing for duration of enrollment in HIV care (ART: n = 1; no ART: n = 2), ART (n = 1), and BMI (ART: n = 27; no ART n = 17).
cP < 0.05 for comparison between participants on ART and not on ART.
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Table 2
Participant characteristics stratified by presence or absence of pulmonary tuberculosis diagnosisa,b.
Characteristics PTB, N (%) No PTB, N (%)
65 (8.8) 672 (91.2)
On ARTc 31 (47.7) 491 (73.1)
Site
    Hospital A 27 (41.5) 363 (54.0)
    Hospital B 38 (58.5) 309 (46.0)
Sex
    Male 18 (27.7) 157 (23.4)
    Female 47 (72.3) 515 (76.6)
Median age (years) (IQR) 38.3 (30.6–46.6) 36.3 (31.0–44.6)
Previous TBc 10 (15.4) 274 (40.8)
Median CD4+ cell count (cells/μl) (IQR)c 263 (98–412) 323 (187–473)
Median BMI (kg/m2) (IQR)c 21.3 (19.3–23.8) 24.2 (21.2–28.5)
Median duration of enrollment in HIV care (days) (IQR)c 548 (30–1500) 875 (327–1772)
Median duration of ART (days) (IQR)d 642 (360–1681) 800 (435–1413)
Abnormal chest radiograph 43 (69.4) 370 (57.5)
aART, antiretroviral therapy; IQR, interquartile range; PTB, diagnosis of pulmonary tuberculosis.
b
Data missing for duration of enrollment in HIV care (PTB: n = 2; No PTB: n = 1); duration of ART 9PTB: n = 0; No PTB: n = 1); BMI (PTB: n = 
6; No PTB: n = 38); and CXR (PTB: n = 3; no PTB: n = 29).
cP < 0.05 for comparison between PTB and No PTB groups.
dAmong participants on ART.
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